Distribution of estrogen receptor ? immunoreactivity in the rat central nervous system

2001 ◽  
Vol 436 (1) ◽  
pp. 64-81 ◽  
Author(s):  
Paul J. Shughrue ◽  
Istvan Merchenthaler
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Estrogen Receptor

Membrane-associated estrogen receptor and caveolin-1 are present in central nervous system myelin and oligodendrocyte plasma membranes

2004 ◽  
Vol 75 (5) ◽  
pp. 603-613 ◽  
Author(s):  
Dina N. Arvanitis ◽  
Huimin Wang ◽  
Richard D. Bagshaw ◽  
John W. Callahan ◽  
Joan M. Boggs
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Estrogen Receptor ◽  
Plasma Membranes ◽  
Caveolin 1

scholarly journals Molecular Imaging Provides Novel Insights on Estrogen Receptor Activity in Mouse Brain

2008 ◽  
Vol 7 (6) ◽  
pp. 7290.2008.00027 ◽  
Author(s):  
Alessia Stell ◽  
Silvia Belcredito ◽  
Paolo Ciana ◽  
Adriana Maggi
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Estrogen Receptor ◽  
Estrogen Receptors ◽  
Transcriptional Activity ◽  
Receptor Activity ◽  
Male And Female ◽  
Estrogen Receptor Activity ◽  
The Central Nervous System ◽  
Set Up

Estrogen receptors have long been known to be expressed in several brain areas in addition to those directly involved in the control of reproductive functions. Investigations in humans and in animal models suggest a strong influence of estrogens on limbic and motor functions, yet the complexity and heterogeneity of neural tissue have limited our approaches to the full understanding of estrogen activity in the central nervous system. The aim of this study was to examine the transcriptional activity of estrogen receptors in the brain of male and female mice. Exploiting the ERE-Luc reporter mouse, we set up a novel, bioluminescence-based technique to study brain estrogen receptor transcriptional activity. Here we show, for the first time, that estrogen receptors are similarly active in male and female brains and that the estrous cycle affects estrogen receptor activity in regions of the central nervous system not known to be associated with reproductive functions. Because of its reproducibility and sensitivity, this novel bioluminescence application stands as a candidate as an innovative methodology for the study and development of drugs targeting brain estrogen receptors.

scholarly journals Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system

2017 ◽  
Vol 12 (8) ◽  
pp. 1231 ◽  
Author(s):  
Christian Guerra-Araiza ◽  
JuliaJ Segura-Uribe ◽  
Rodolfo Pinto-Almazán ◽  
Angélica Coyoy-Salgado ◽  
ClaudiaE Fuentes-Venado
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Estrogen Receptor ◽  
Cytoskeletal Proteins ◽  
Estrogen Receptor Modulators ◽  
The Central Nervous System ◽  
Receptor Modulators

scholarly journals Selective estrogen receptor modulators (SERMS)

2006 ◽  
Vol 50 (4) ◽  
pp. 720-734 ◽  
Author(s):  
Adolfo Diez-Perez
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Estrogen Receptor ◽  
Bone Density ◽  
Bone Turnover ◽  
Estrogen Receptor Alpha ◽  
Turnover Rate ◽  
Hormone Receptors ◽  
Estrogen Receptor Beta

Hormone receptors and, specifically, estrogen receptors were described about four decades ago. For estrogens, there are two receptors, estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta). The two receptors are coded by different genes and their tissue expression varies across organs. ERalpha is predominantly expressed in reproductive tissues (uterus, breast, ovaries) liver and central nervous system, whereas ERbeta is expressed in other tissues such as bone, endothelium, lungs, urogenital tract, ovaries, central nervous system and prostate. More than seventy molecules that belong to the SERMS class have been described. There are 5 chemical groups: triphenylethylenes, benzotiophenes, tetrahydronaphtylenes, indoles and benzopyrans. All of these non-hormonal compounds are capable of activating the ER, reduce bone turnover rate and, as an antiresorptive, clearly improve bone density. Estrogens reduce bone turnover rate and, as an antiresorptive, clearly improve bone density. They are also beneficial for the relief of menopausal symptoms. An ongoing debate that extends over the decades, relates to to overall benefit/risk profile of estrogen or estrogen-progestin therapy since these therapies can increase the risk of serious health disorders, such as breast cancer. SERMs have increased our understanding of hormone-receptor regulatory mechanisms. Their development has permitted a targeted efficacy profile avoiding some of the side effects of the hormone therapy. Their clinical utility relies today mostly on the effects on breast cancer and bone.

Luminal Subtypes Predict Improved Survival Following Central Nervous System Metastasis in Patients With Surgically Managed Metastatic Breast Carcinoma

2014 ◽  
Vol 138 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Andrea L. Wiens ◽  
Sarah E. Martin ◽  
Elizabeth C. Bertsch ◽  
Gail H. Vance ◽  
Ryan A. Stohler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Estrogen Receptor ◽  
Metastatic Breast Cancer ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Metastatic Breast ◽  
Luminal A ◽  
Luminal B

Context.—Metastatic breast cancer to the central nervous system (CNS) is second only to lung cancer metastasis to the CNS in frequency. Patients with triple-negative primary breast cancer and those with human epidermal growth factor receptor 2 (HER2)–positive primary breast cancer are at an increased risk for metastasis. Very little is known about predictive or prognostic variables once patients develop CNS metastases. Currently, therapeutic options are limited, with surgery generally offered primarily to those with solitary lesions. Context.—To determine the influence of molecular subtypes of metastatic breast cancer on survival from the time of CNS metastasis and to aid in the prognostic stratification of these patients. Design.—We identified 59 cases of metastatic breast cancer to the CNS and analyzed them for various demographic and clinicopathologic parameters. Tumors were categorized into molecular subtypes using immunohistochemical methods: luminal A [estrogen receptor (ER)+/Ki67low], luminal B (ER+/Ki67 high), intrinsic HER2 (ER−/HER2+), and triple-negative. Survival after CNS metastasis for each group was plotted using a Kaplan-Meier curve, and multivariate analysis was performed. Results.—Patients with metastases from luminal tumors had a statistically significant survival advantage when compared with those of the triple-negative phenotype. Importantly, survival among patients with luminal A and luminal B tumors was not significantly different. Similarly, patient's age, histologic grade, and number of lesions did not contribute to determining outcomes. Conclusions.—Estrogen receptor positivity (ie, luminal phenotype) of tumors appears to determine outcomes after development of metastases. In contrast, proliferation rate had little or no effect on the long-term survival. Understanding the biology of metastases can help stratify patients into prognostically meaningful categories and tailor treatment regimens for individual patients.

Sign in / Sign up

Export Citation Format

Share Document